(R,R)-MK287 is a tetrahydrofuran derivative that acts as a potent and stereospecific competitive inhibitor of [3H]C18-PAF binding to human platelets, polymorphonuclear leukocytes (PMNs), and lung membranes. It effectively and selectively inhibits PAF-induced platelet aggregation (ED50 = 56 ± 38 nM; or ED50 = 1.5 ± 0.5 nM in gel-filtered platelets) and elastase release from PMNs (ED50 = 4.4 ± 2.6 nM). In vivo, it inhibits PAF-induced lethality in mice (ED50 = 0.8 mg/kg, oral) and PAF-induced bronchospasm in guinea pigs (ED50 = 0.18 mg/kg, intraduodenal; ED50 = 0.19 mg/kg, intravenous). The compound shifts the concentration-response curve of PAF-induced platelet aggregation to the right, indicating functional antagonism of PAF activity.